Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.4%

2 terminated out of 37 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

22%

8 trials in Phase 3/4

Results Transparency

0%

0 of 20 completed with results

Key Signals

91% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (7)
P 1 (3)
P 2 (4)
P 3 (6)
P 4 (2)

Trial Status

Completed20
Recruiting8
Unknown5
Terminated2
Enrolling By Invitation1
Not Yet Recruiting1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (37)

Showing 20 of 20 trials
NCT04557969Recruiting

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

NCT06495645Not ApplicableRecruitingPrimary

Miss Rate of Gastric Neoplasms Under Computer-aided Endoscopy

NCT04780256Recruiting

Endoscopic Resection of Gastrointestinal Neoplasms

NCT06977061Phase 2Not Yet RecruitingPrimary

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

NCT06969794CompletedPrimary

Single-center, Randomized, Superiority Pivotal Clinical Study to Evaluate the Efficacy of Artificial Intelligence-based Upper Gastrointestinal Endoscopy Image

NCT06028737Phase 2Recruiting

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

NCT04032119Phase 3CompletedPrimary

RCT of Gastric ESD With or Without Epineprhine Added Solution

NCT06923020Enrolling By InvitationPrimary

Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Cancer.

NCT03597581Phase 1Completed

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

NCT03429816Not ApplicableCompletedPrimary

OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma

NCT05804331Recruiting

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

NCT06702683Recruiting

The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer

NCT06342427Completed

Stomach Cancer Exosome-based Detection

NCT06362070Not ApplicableRecruiting

Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy

NCT06281379Not ApplicableCompleted

Complete Mesogastric Excision With D2 Lympadenectomy for Gastric Cancer:

NCT03255070Phase 1Completed

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

NCT05688020Phase 4Recruiting

Tranexamic Acid During Upper GI Endoscopic Resection Procedures

NCT05265221Completed

Learning Curve for Gastric Endoscopic Submucosal Dissection

NCT05259488Completed

Preoperative Immunonutrition in Laparoscopic Total D2 Gastrectomy

NCT04622098Unknown

Prevalence of Sub-epithelial Lesions Among Patients Undergoing EGDs in Egypt

Scroll to load more

Research Network

Activity Timeline